



# Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Curigliano, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bedard, Chia-Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine A. Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, and Aung Naing

In the original version of this article (1), the analysis presented in the text, figures (Figs. 1 and 2), and supplementary data (Supplementary Fig. S2; Supplementary Table S1) included data from one patient who withdrew consent after enrollment/data collection but prior to analysis. This error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

## Reference

1. Curigliano G, Curigliano H, Mach N, Doi T, Tai D, Forde PM, et al. Phase I/Ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors. *Clin Cancer Res* 2021;27:3620–9.

Published online September 3, 2024.  
*Clin Cancer Res* 2024;30:3957  
doi: 10.1158/1078-0432.CCR-24-2131  
©2024 American Association for Cancer Research